Menu
Back to User profile » Professor Joo-Youn Cho
Papers published by Professor Joo-Youn Cho:
Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects
Jiang X, Bae S, Yoon DY, Park SJ, Oh J, Cho JY, Yu KS
Drug Design, Development and Therapy 2023, 17:2137-2145
Published Date: 24 July 2023
Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects
Hwang S, Lee DY, Cho JY, Chung JY, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2021, 15:2375-2384
Published Date: 1 June 2021
Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
Jeon I, Oh J, Kwon YK, Yoon SH, Cho JY, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2021, 15:1735-1747
Published Date: 28 April 2021
Evaluation of the effects of food on levodropropizine controlled-release tablet and its pharmacokinetic profile in comparison to that of immediate-release tablet
Lee S, Nam KY, Oh J, Lee S, Cho SM, Choi YW, Cho JY, Lee BJ, Hong JH
Drug Design, Development and Therapy 2018, 12:1413-1420
Published Date: 23 May 2018
Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H:quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials
Kim S, Lee S, Cho JY, Yoon SH, Jang IJ, Yu KS
Drug Design, Development and Therapy 2017, 11:3187-3195
Published Date: 7 November 2017
Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon® and Eprex® following a single subcutaneous administration in healthy male volunteers
Yoon S, Rhee SJ, Heo SJ, Oh TY, Yoon SH, Cho JY, Lee S, Yu KS
Drug Design, Development and Therapy 2017, 11:3127-3135
Published Date: 27 October 2017
A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers
Lee J, Kim BH, Yu KS, Kim HS, Kim JD, Cho JY, Lee S, Gu N
Drug Design, Development and Therapy 2017, 11:1301-1313
Published Date: 24 April 2017
Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects
Shin D, Lee S, Yi S, Yoon SH, Cho JY, Bahng MY, Jang IJ, Yu KS
Drug Design, Development and Therapy 2017, 11:713-723
Published Date: 10 March 2017
Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers
Jang K, Kim M, Oh J, Lee S, Cho JY, Yu KS, Choi TK, Lee SH, Lim KS
Drug Design, Development and Therapy 2017, 11:705-711
Published Date: 9 March 2017
Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects
Rhee SJ, Choi Y, Lee S, Oh J, Kim SJ, Yoon SH, Cho JY, Yu KS
Drug Design, Development and Therapy 2016, 10:2525-2534
Published Date: 10 August 2016
The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan
Gu N, Cho JY, Shin KH, Jang IJ, Rhee MY
Drug Design, Development and Therapy 2016, 10:1525-1531
Published Date: 19 April 2016
Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects
Rhee SJ, Lee S, Yoon SH, Cho JY, Jang IJ, Yu KS
Drug Design, Development and Therapy 2016, 10:1411-1418
Published Date: 13 April 2016
A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles
Chung H, Lee H, Han H, An H, Lim KS, Lee YJ, Cho JY, Yoon SH, Jang IJ, Yu KS
Drug Design, Development and Therapy 2015, 9:2609-2616
Published Date: 13 May 2015
Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
Gu N, Park MK, Kim TE, Bahng MY, Lim KS, Cho SH, Yoon SH, Cho JY, Jang IJ, Yu KS
Drug Design, Development and Therapy 2014, 8:1709-1721
Published Date: 6 October 2014
Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects
Cha YJ, Lim KS, Park MK, Schneider S, Bray B, Kang MC, Chung JY, Yoon SH, Cho JY, Yu KS
Drug Design, Development and Therapy 2014, 8:1613-1619
Published Date: 26 September 2014
Novel nanocrystal formulation of megestrol acetate has improved bioavailability compared with the conventional micronized formulation in the fasting state
Jang K, Yoon S, Kim SE, Cho JY, Yoon SH, Lim KS, Yu KS, Jang IJ, Lee H
Drug Design, Development and Therapy 2014, 8:851-858
Published Date: 25 June 2014
Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers
Yoon S, Lee H, Kim TE, Lee S, Chee DH, Cho JY, Yu KS, Jang IJ
Drug Design, Development and Therapy 2014, 8:123-128
Published Date: 15 January 2014